This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cucuianu, D. M. Search for Related Content PubMed PubMed Citation Articles by Cucuianu, D. M. Related Collections Pathophysiology Coagulation and fibronolysis Lipid and lipoprotein metabolism

(Circulation. 2000;101:e158.)
© 2000 American Heart Association, Inc.

Circulation Electronic Pages

Factor XIII and Fibrinolytic Resistance

Dr Mircea Cucuianu

Professor of Clinical Chemistry Medical Clinic Nr I, R-3400 Cluj-Napoca, Romania, E-mail hemato@codec.ro

	Introduction

 
To the Editor

Reed and Houng¹ demonstrated that factor XIII-mediated cross-linking plays a critical role in limiting fibrinolysis in experimentally formed pulmonary emboli. They suggested that factor XIII could facilitate the growth of new or forming thrombi. This concept is supported by my observations, which began 26 years ago and emphasize increased plasma factor XIII levels in hypertriglyceridemic patients^{2 3 4} who also display high plasma fibronectin concentrations⁴ and an obviously prolonged dilute blood clot lysis time.⁵ Because the in vitro inhibition of factor XIII by p-chloromercuribenzoate led to an acceleration of clot lysis,⁵ I presumed that the association of high plasma factor XIII levels with impaired fibrinolysis was not merely casual. My colleagues and I also showed that platelet factor XIII is unlikely to make any significant contribution to plasma factor XIII levels.³ However, the significant correlations between liver-secreted serum cholinesterase and plasma factor XIII and fibronectin, as well as data obtained in patients with severely impaired hepatic protein synthesis (decompensated liver cirrhosis) or compensatively enhanced secretion of plasma proteins (nephrotic syndrome) provide circumstantial evidence that the liver is the main contributor to plasma factor XIII and fibronectin.⁴ Presumably, overloading the liver with lipids in a patient with insulin resistance would stimulate the synthesis of factor XIII, fibronectin, and serum cholinesterase. It is also reasonable to presume that thrombi richer in factor XIII and fibronectin would not only be more resistant to fibrinolysis but also more readily attached to the vessel wall. It is hoped that the convincing results reported by . . . [Full Text of this Article]